Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several…
$EXEL nice breakout. sadly, no position here https://t.co/BkS8AWYgkW https://t.co/0gyKkBOMYH
$EXEL https://t.co/i3FzIvpGe7
18 analysts rate EXEL Hold on consensus.
Consensus price target: $55.53 (-13.95% downside from $64.53)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Beckerle Mary C director | Aug 10, 2026 | Sale | 9,812 | $526.51K |
| WYSZOMIERSKI JACK L director | Jun 1, 2026 | Sale | 3,925 | $198.41K |
| Eckhardt Sue Gail director | Jun 1, 2026 | Sale | 9,812 | $491.97K |
| Aftab Dana EVP, Research and Development | May 26, 2026 | Sale | 43,451 | $2.19M |
| Haley Patrick J. EVP, Commercial | May 20, 2026 | Sale | 32,110 | $1.6M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2026 | $2.32B | +6.98% | $782.57M |
| 2025 | $2.17B | 0% | $521.27M |
| 2024 | $2.17B | +18.49% | $521.27M |
Stock data for EXEL: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics